Vinpocetine as a potent antiinflammatory agent.
作者信息
Medina Alexandre E
机构信息
Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA 23236, USA.
出版信息
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):9921-2. doi: 10.1073/pnas.1005138107. Epub 2010 May 21.
Abstract
摘要
相似文献
1
Vinpocetine as a potent antiinflammatory agent.
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):9921-2. doi: 10.1073/pnas.1005138107. Epub 2010 May 21.
2
Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure.
J Neurosci. 2006 Jan 18;26(3):1057-60. doi: 10.1523/JNEUROSCI.4177-05.2006.
3
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Cell Physiol Biochem. 2012;30(3):711-22. doi: 10.1159/000341451. Epub 2012 Aug 1.
4
[Cyclic GMP mimicks potentiation effect of the nootropic agent vinpocetine on the high threshold A-current in the mollusk neurons].
Ross Fiziol Zh Im I M Sechenova. 1998 Aug;84(8):741-6.
5
Vinpocetine: An Unapproved Drug Sold as a Dietary Supplement.
Mayo Clin Proc. 2015 Oct;90(10):1455. doi: 10.1016/j.mayocp.2015.07.008.
6
[The nootropic agent vinpocetine blocks the delayed rectifier potassium channel more strongly than the high-conductance calcium channel].
Zh Vyssh Nerv Deiat Im I P Pavlova. 1996 Sep-Oct;46(5):911-6.
7
[Effect of vinpocetine on various high threshold potassium currents in the mollusk neurons].
Biull Eksp Biol Med. 1998 Oct;126(10):408-11.
8
Repurposing of the Nootropic Drug Vinpocetine as an Analgesic and Anti-Inflammatory Agent: Evidence in a Mouse Model of Superoxide Anion-Triggered Inflammation.
Mediators Inflamm. 2019 Mar 31;2019:6481812. doi: 10.1155/2019/6481812. eCollection 2019.
9
Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9795-800. doi: 10.1073/pnas.0914414107. Epub 2010 May 6.
10
Role of vinpocetine in cerebrovascular diseases.
Pharmacol Rep. 2011;63(3):618-28. doi: 10.1016/s1734-1140(11)70574-6.
引用本文的文献
1
In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia.
Clin Psychopharmacol Neurosci. 2025 Feb 28;23(1):15-31. doi: 10.9758/cpn.24.1229. Epub 2024 Dec 3.
2
Unlocking vinpocetine's oncostatic potential in early-stage hepatocellular carcinoma: A new approach to oncogenic modulation by a nootropic drug.
PLoS One. 2024 Oct 31;19(10):e0312572. doi: 10.1371/journal.pone.0312572. eCollection 2024.
3
Atheroprotective role of vinpocetine: an old drug with new indication.
Inflammopharmacology. 2024 Dec;32(6):3669-3678. doi: 10.1007/s10787-024-01529-5. Epub 2024 Aug 14.
4
The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis.
J Inflamm (Lond). 2024 Jun 10;21(1):19. doi: 10.1186/s12950-024-00394-x.
5
Synthesis and pharmacological activity of vinpocetine derivatives.
RSC Adv. 2024 Mar 7;14(12):7981-7991. doi: 10.1039/d3ra07325d. eCollection 2024 Mar 6.
6
Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis.
J Taibah Univ Med Sci. 2023 Sep 20;19(1):35-53. doi: 10.1016/j.jtumed.2023.09.002. eCollection 2024 Feb.
7
New insights on the potential effect of vinpocetine in Parkinson's disease: one of the neglected warden and baffling topics.
Metab Brain Dis. 2023 Aug;38(6):1831-1840. doi: 10.1007/s11011-023-01254-y. Epub 2023 Jun 19.
8
We are all aging, and here's why.
Aging Med (Milton). 2022 Oct 3;5(3):211-231. doi: 10.1002/agm2.12223. eCollection 2022 Sep.
9
Vinpocetine-based therapy is an attractive strategy against oxidative stress-induced hepatotoxicity in vitro by targeting Nrf2/HO-1 pathway.
EXCLI J. 2021 Mar 4;20:550-561. doi: 10.17179/excli2021-3463. eCollection 2021.
10
FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
Cancer Res. 2020 Aug 15;80(16):3200-3214. doi: 10.1158/0008-5472.CAN-19-4044. Epub 2020 Jun 30.
本文引用的文献
1
Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9795-800. doi: 10.1073/pnas.0914414107. Epub 2010 May 6.
2
Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation.
Neurosci Lett. 2010 Apr 12;473(3):202-7. doi: 10.1016/j.neulet.2010.02.046. Epub 2010 Feb 26.
3
Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor.
Eur J Pharmacol. 2009 Oct 12;620(1-3):49-56. doi: 10.1016/j.ejphar.2009.08.027. Epub 2009 Aug 21.
4
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.
Respir Med. 2009 Jul;103(7):975-94. doi: 10.1016/j.rmed.2009.01.003. Epub 2009 Apr 15.
5
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Lancet Neurol. 2009 Apr;8(4):382-97. doi: 10.1016/S1474-4422(09)70062-6.
6
Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Curr Opin Investig Drugs. 2007 May;8(5):364-72.
7
Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease.
Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5;144B(3):300-4. doi: 10.1002/ajmg.b.30435.
8
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.
Neurobiol Aging. 2007 May;28(5):639-47. doi: 10.1016/j.neurobiolaging.2006.03.013. Epub 2006 May 11.
9
Phosphodiesterase inhibitors in airways disease.
Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. doi: 10.1016/j.ejphar.2005.12.059. Epub 2006 Feb 2.
10
The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease.
Expert Opin Investig Drugs. 2004 Nov;13(11):1469-81. doi: 10.1517/13543784.13.11.1469.
Zotero 插件